▲ Peaking
Business
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
A 40.5% remission rate in a phase‑2 trial could reshape treatment hopes for Crohn's disease patients.
Crohn's Disease
2 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Crohn's Disease
This hub groups 2 separate news trends connected to Crohn's Disease, spanning August 5, 2026 through October 19, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 11 article observations and 11 source signals, led by Business, Science coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Science
🔮 fades ✓
3D DNA mapping in rare immune cells reveals new genes linked with autoimmune disease risk
Scientists have identified 100 genes linked to Crohn’s disease risk by mapping 3D DNA in rare immune cells